Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -.--% |
|
-.--% | -.--% |
2023 | Genocea Biosciences, Inc. Went Out of Business | CI |
2023 | Liquidation Plan Approved for Genocea Biosciences, Inc. | CI |
Financials (USD)
Sales 2020 | 1.36M | Sales 2021 | 1.64M | Capitalization | 66.64M |
---|---|---|---|---|---|
Net income 2020 | -43M | Net income 2021 | -33M | EV / Sales 2020 | 50.8 x |
Net cash position 2020 | 55.9M | Net cash position 2021 | 19.96M | EV / Sales 2021 | 28.4 x |
P/E ratio 2020 |
-2.18
x | P/E ratio 2021 |
-2.4
x | Employees | 74 |
Yield 2020 * |
-
| Yield 2021 |
-
| Free-Float | 100% |
![Extreme 0](/images/extremecours_fleche.png)
![Extreme 0](/images/extremecours_fleche.png)
![Extreme 0](/images/extremecours_fleche.png)
![Extreme 0](/images/extremecours_fleche.png)
![Extreme 0](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 52 | 07-02-28 | |
Girish Aakalu
PRN | Corporate Officer/Principal | - | 18-12-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ken Bate
CHM | Chairman | 73 | 14-09-10 |
1st Jan change | Capi. | |
---|---|---|
-.--% | 58 | |
+17.72% | 44.44B | |
-10.33% | 37.99B | |
+37.55% | 37.75B | |
+29.36% | 30.78B | |
-8.44% | 27.38B | |
+12.45% | 26.17B | |
+44.19% | 14.15B | |
+31.93% | 12.59B | |
-7.67% | 11.28B |
- Stock Market
- Equities
- GNCAQ Stock